Drug Profile
Marstacimab - Pfizer
Alternative Names: PF-06741086; PF-6741086Latest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihaemorrhagics; Coagulants; Monoclonal antibodies
- Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Haemophilia
Most Recent Events
- 11 Dec 2023 Preregistration for Haemophilia (Hemophilia A and Hemophilia B) (In adolescents, In children, In the elderly, In adults) in European Union (SC)
- 11 Dec 2023 Preregistration for Haemophilia (Hemophilia A and Hemophilia B) (In adolescents, In children, In the elderly, In adults) in USA (SC)
- 11 Dec 2023 A European Commission decision for MAA for Marstacimab for Hemophilia (Hemophilia A and Hemophilia B) is expected by the first quarter of 2025